




RealRate

# PHARMACEUTICAL 2019

Kura Oncology Inc.  
Rank 128 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2019

Kura Oncology Inc.  
Rank 128 of 371

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 323% points. The greatest weakness of Kura Oncology Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 222% points.

The company's Economic Capital Ratio, given in the ranking table, is -67%, being 264% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	181,197
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,615
Liabilities, Non-Current	7,779
Other Assets	1,182
Other Compr. Net Income	-82
Other Expenses	62,883
Other Liabilities	0
Other Net Income	2,436
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	182,379
Liabilities	21,394
Expenses	62,883
Stockholders Equity	160,985
Net Income	-60,447
Comprehensive Net Income	-60,488
Economic Capital Ratio	-67%

